PNT POINT Biopharma Global Inc.

POINT Biopharma Global Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of radioligand therapies for the treatment of cancer. Its products include PNT2001, a PSMA radioligand that is in preclinical studies for early stage prostate cancer treatment; PNT2002, which is in Phase 3 studies to evaluate superiority to the standard of care in mCRPC patients; PNT2003, a somatostatin-targeted radioligand therapy that is in Phase 3 trials for the treatment of patients with somatostatin receptor-positive neuroendocrine tumors; and PNT2004, a radioligand that targets fibroblast activation protein-a. The company is based in Indianapolis, Indiana.

$7.95  -0.37 (-4.39%)
As of 12/03/2021 11:03:43 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  07/08/2020
Outstanding shares:  90,121,794
Average volume:  139,124
Market cap:   $784,960,826
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    730541109
ISIN:        US7305411099
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   2.78
PS ratio:   0.00
Return on equity:   -10.20%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy